Brief Pause, Big Stakes: FDA Extends Review Of Denali’s Hunter Syndrome Therapy

 
• By Sushmita Panda
  
A white paper with hunter syndrome written on it in bold letters
Hunter syndrome, also known as MPS II, is a rare genetic lysosomal storage disease caused by mutations in the iduronate-2-sulfatase (IDS) gene. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D